May 01,2018

Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research

Today, Flatiron Health, a market leader in the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, announced the publication of a pivotal study validating the quality of Flatiron’s mortality endpoint and illustrating the potential impact for research conducted with contemporary real-world datasets. The published study details how investigators created a novel real-world mortality endpoint using multiple data sources to supplement Flatiron’s curated electronic health record data, collected from the company’s network of over 2,500 oncology clinicians.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
May 01,2018

Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement

Bristol-Myers Squibb and Flatiron Health expanded their relationship today by announcing a three-year collaboration agreement. Bristol-Myers Squibb will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. With the expanded collaboration, the two companies intend to form a joint Scientific Advisory Board to advance the use of RWE for regulatory decision making.

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Feb 01,2018

Roche to Acquire Flatiron Health to Accelerate Industry-Wide Development and Delivery of Breakthrough Medicines for Patients with Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018. Under the terms of the agreement, Roche will make a payment of USD 1.9 billion to Flatiron Health on a fully diluted basis, subject to certain adjustments.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 05,2017

Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer

Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes. The two companies will collaborate to explore development of a cognitive solution that uses real-world data and advanced analytical techniques with the aim to provide better insights on the expected outcomes of breast cancer treatment options.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 01,2016

Flatiron Health and Foundation Medicine Unveil Powerful Oncology Information Resource to Advance Precision Medicine

Flatiron Health and Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted therapeutics and immunotherapies to treat cancer. The clinico-genomic database, containing information on nearly 20,000 patients, is one of the largest and most comprehensive information efforts of its kind in oncology. The HIPAA-compliant database integrates rich genomic profiling data from patients whose tumors were sequenced with Foundation Medicine’s comprehensive genomic profiling (CGP) assays with annotated longitudinal clinical and outcomes data developed by Flatiron from electronic health records (EHR).

PRODUCT

#big data

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
Apr 01,2016

Flatiron Health Announces Strategic Relationships with Celgene and Amgen to Further Advance Personalized Medicine for Cancer Patients and Accelerate Clinical Research

Flatiron Health today announced an expansion of its relationships with Celgene Corporation and Amgen Inc. Through individual agreements, Celgene and Amgen will collaborate with Flatiron Health with the goals of accelerating clinical research, advancing personalized medicine and enhancing treatment options for cancer patients. In addition, Celgene Switzerland LLC and Amgen Ventures have invested in Flatiron Health’s recently announced fundraising round.

COLLABORATION PARTNERSHIP

#r&d

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
Jul 31,2015

Astellas Establishes New Real World Informatics and Analytics Function

Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real World Informatics and Analytics (RWI) function, effective July 1, 2015. The RWI function is headquartered in Northbrook, Illinois, the United States, with employees located in all regions. Nathan R. Crisel, formerly Director, Corporate Strategy and Planning and SIM, Astellas US LLC, leads the new function and reports directly to Chief Strategy Officer, Kenji Yasukawa, Ph.D.

PRODUCT

#rwd

#big data

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD